ConductScience.org, home
Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy
API referenceFor AI assistants

Trial · NCT03340675

Results by group62

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 62

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Incidence of Treatment-Emergent Adverse EventsHigh Dose IfetrobanAny TEAE14Participants
Incidence of Treatment-Emergent Adverse EventsLow Dose IfetrobanAny TEAE9Participants
Incidence of Treatment-Emergent Adverse EventsPlaceboAny TEAE10Participants
Pharmacokinetics Area Under the CurveHigh Dose IfetrobanIfetroban3196Standard Deviation 2485h*ng/mL
Pharmacokinetics Area Under the CurveLow Dose IfetrobanIfetroban761Standard Deviation 585h*ng/mL
Pharmacokinetics Area Under the CurveHigh Dose IfetrobanIfetroban Glucuronide45116Standard Deviation 30211h*ng/mL
Pharmacokinetics Area Under the CurveLow Dose IfetrobanIfetroban Glucuronide13789Standard Deviation 9700h*ng/mL
Pharmacokinetics Maximum Serum Concentration (Cmax)High Dose IfetrobanIfetroban1560Standard Deviation 2028ng/mL
Pharmacokinetics Maximum Serum Concentration (Cmax)Low Dose IfetrobanIfetroban272Standard Deviation 300ng/mL
Pharmacokinetics Maximum Serum Concentration (Cmax)High Dose IfetrobanIfetroban Glucuronide9787Standard Deviation 7148ng/mL
Pharmacokinetics Maximum Serum Concentration (Cmax)Low Dose IfetrobanIfetroban Glucuronide2276Standard Deviation 1955ng/mL
Pharmacokinetics Time to Reach Cmax (Tmax) ConcentrationHigh Dose IfetrobanIfetroban0.71Standard Deviation 0.24h
Pharmacokinetics Time to Reach Cmax (Tmax) ConcentrationLow Dose IfetrobanIfetroban1.09Standard Deviation 1.2h
Pharmacokinetics Time to Reach Cmax (Tmax) ConcentrationHigh Dose IfetrobanIfetroban Glucuronide2.81Standard Deviation 6.43h
Pharmacokinetics Time to Reach Cmax (Tmax) ConcentrationLow Dose IfetrobanIfetroban Glucuronide1.89Standard Deviation 2.47h
Pharmacokinetics Plasma Terminal Half-life ConcentrationHigh Dose Ifetroban12.96Standard Deviation 5.73h
Pharmacokinetics Plasma Terminal Half-life ConcentrationLow Dose Ifetroban8.99Standard Deviation 4.6h
Change From Baseline in Left Ventricular Ejection FractionHigh Dose Ifetroban1.8Standard Deviation 5.44Percentage of LVEF
Change From Baseline in Left Ventricular Ejection FractionLow Dose Ifetroban0Standard Deviation 5.16Percentage of LVEF
Change From Baseline in Left Ventricular Ejection FractionPlacebo-1.5Standard Deviation 3.27Percentage of LVEF

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03340675/results

API referenceFor AI assistants